Lamivudine, Doravirine, Tenofovir Disoproxil

5 trials 2 recruiting JAnti-infectives

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

5 Sponsors

7 Countries

Phase III

Phase II

Phase IV

Phase III: 2 Phase II: 1 Phase IV: 2

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

Indications tested

HIV infection 1

Sponsors using this IMP

Centre Hospitalier Universitaire De Caen Normandie 1 Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La Ciencia 1 Gilead Sciences Inc. 1 Inserm 1 Radboud universitair medisch centrum Stichting 1

All trials

5 total

ANRS0392s ELDORADO : Phase III, open-label, randomized, multicenter trial EvaLuating the non-inferiority of DORAvirine versus DOlutegravir b… Recruiting

2023-508626-10-00 Phase III 1 country Inserm
Efficacy of the Doravirine/Tenofovir Disoproxil Fumarate/Lamivudine combination in people living with HIV with a history of M184V/I mutation… Recruiting

2023-505845-17-00 Phase II 1 country Centre Hospitalier Universitaire De Caen Normandie
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 ( ISLEND-… Ended

2024-514047-28-00 Phase III 4 countries Gilead Sciences Inc.
Impact of Doravirine in Liver Steatosis and Fibrosis in PLWH. A pilot, proof of concept study (DORALI Study) Ended

2023-504952-87-00 Phase IV 1 country Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocio…
Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Ended

2024-515487-31-00 Phase IV 5 countries Stichting Radboud universitair medisch centrum

Showing 1–5 of 5 trials

← All drugs A–Z